Prior to joining the company, Dr. Kraus was Vice President, Drug Development Services for ICON pls, a global clinical research organization. Prior to that, Dr. Kraus was a vice president and medicine development leader at GlaxoSmithKline for more than 12 years, including eight years within the Neurosciences Therapy Area Unit, ultimately as Head of Medical Governance. There, he led, contributed to or managed drug development programs in schizophrenia, major depressive disorder, anxiety disorders, bipolar disorder, Duchene muscular dystrophy, multiple sclerosis, epilepsy, Parkinson’s disease, Alzheimer’s disease, neuropathic pain and neuroinjury.

John received his MD and PhD (neurobiology) from Duke University in Durham, NC. He completed his psychiatry residency training at the University of North Carolina, Chapel Hill, NC, where he was also Chief Resident. Prior to joining GSK, Dr. Kraus was Assistant Professor of Psychiatry at UNC and Head, Adult Admissions Psychiatry, at Dorothea Dix Hospital in Raleigh, NC. At Dix, John supervised the treatment of ≈3,000 patients per year, including those with severe mental illness, substance use disorders and dual-diagnoses. He was also Associate Director of the UNC Psychiatry Clinical Research Unit, where he was an investigator on a number of schizophrenia clinical trials. He is a Diplomate, American Board of Psychiatry & Neurology, and a Distinguished Fellow of the American Psychiatric Association.